What are the NCCN guidelines for the management of colon cancer with liver metastases?

NCCN Guidelines for Colon Cancer with Liver Metastases

For resectable liver metastases, perioperative chemotherapy with FOLFOX (3 months before and 3 months after surgery) is the standard approach, while unresectable disease requires doublet chemotherapy plus bevacizumab or EGFR inhibitors (for RAS wild-type left-sided tumors). 1, 2

Resectable Liver Metastases

Primary Treatment Strategy

Perioperative chemotherapy is the established standard for patients with resectable liver metastases 2:

• 3 months preoperative FOLFOX → surgical resection → 3 months postoperative FOLFOX
• This approach demonstrated superior disease-free survival in the EORTC 40983 trial for patients with up to 4 liver metastases and no extrahepatic disease 2

Special Considerations for Resectable Disease

Single small metastases (<2 cm) may proceed directly to surgery since lesions can disappear with chemotherapy and become undetectable intraoperatively. In this scenario, give 6 months of postoperative FOLFOX 2.

Patients who failed adjuvant oxaliplatin within 12 months should receive FOLFIRI instead of FOLFOX in the perioperative setting, or proceed directly to surgery if feasible 2.

Synchronous presentation (primary tumor intact):

• If clearly resectable: Consider simultaneous or staged resection of primary and metastases, followed by 3 months postoperative FOLFOX 2
• If borderline resectable: Give 3 months preoperative FOLFOX, reassess for resectability 2

Critical Pitfall: Avoiding Complete Response

Close monitoring during neoadjuvant therapy is mandatory to prevent complete radiographic disappearance of lesions, which complicates surgical planning 2. Reassess every 12-16 weeks, as maximal response typically occurs by this timeframe 3. If anatomical resection is planned, complete response is manageable; otherwise, use MRI, PET, or contrast-enhanced ultrasound to locate vanished lesions 2.

Unresectable or Borderline Resectable Liver Metastases

First-Line Systemic Therapy Selection

The choice depends on molecular profile and primary tumor location 1:

For MSI-H/dMMR tumors:

• Pembrolizumab monotherapy is the preferred first-line treatment 1

For MSS/pMMR RAS wild-type tumors:

• Left-sided primary: Chemotherapy doublet (FOLFOX or FOLFIRI) + anti-EGFR therapy (cetuximab or panitumumab) 1
• Right-sided primary: Chemotherapy doublet + bevacizumab 1

For RAS mutant tumors:

• Chemotherapy doublet + bevacizumab 3
• Alternative: FOLFOXIRI ± bevacizumab for fit patients requiring aggressive cytoreduction 3

Conversion to Resectability Strategy

Intensive upfront chemotherapy aims to convert unresectable disease 4:

• FOLFIRI or FOLFOX or CapeOX: 41% of experts recommend this approach 4
• Chemotherapy + bevacizumab: 47% of experts recommend adding bevacizumab 4
• For unresectable liver-only or lung-only metastases, 86% of experts add bevacizumab to active chemotherapy 4

Reassess every 3-4 months with multidisciplinary team review. If resectability is achieved, proceed to surgery followed by completion of total 6 months of systemic therapy 2.

Progression During Neoadjuvant Treatment

Do not proceed directly to surgery if disease progresses during preoperative chemotherapy 2. This indicates aggressive tumor biology with poor prognosis even after resection. Switch to best available salvage chemotherapy instead 2.

Ablative and Local Therapies

When Surgery Is Not Feasible

Stereotactic body radiation therapy (SBRT) is recommended following systemic therapy for oligometastatic liver disease in non-surgical candidates 1. This represents a safe alternative to radiofrequency ablation 4, 3.

Radiofrequency ablation (RFA) can be used:

• As adjunct to surgery to eradicate all visible metastatic sites 3
• As alternative to surgery in patients unsuitable for resection 5

Radioembolization with yttrium-90 may be considered for liver-limited disease failing standard chemotherapy, but should be limited to clinical trials in earlier treatment lines 3.

Selective internal radiation therapy (SIRT) is NOT routinely recommended for unilobar or bilobar liver metastases 1.

Surgical Considerations

Bevacizumab and Surgery Timing

Stop bevacizumab at least 6 weeks before elective surgery (corresponding to 2 half-lives) to minimize wound healing complications 6, 7. Similarly, delay restarting bevacizumab for 6-8 weeks postoperatively 7.

Surgeon and Center Volume

Operations should be performed at centers conducting >50 colorectal surgeries per year by surgeons experienced in colorectal surgery and total mesorectal excision 4. Surgeon experience and center volume are independent factors affecting outcomes 4.

Extrahepatic Disease

Resectable lung metastases can be resected with 5-year survival similar to liver metastases, particularly in highly selected patients 5. Thoracic lymph node involvement and elevated CEA predict reduced survival 5.

Uncontrolled extrahepatic disease is a contraindication to liver resection 5.

Key Algorithmic Decision Points

1. Assess resectability with hepatobiliary surgeon and radiologist experienced in CRLM
2. Check molecular profile: MSI status, RAS/BRAF mutations, primary tumor location
3. If resectable upfront: Perioperative FOLFOX (3+3 months) unless single <2cm lesion
4. If unresectable: Intensive chemotherapy ± biologics based on molecular profile
5. Reassess every 12-16 weeks for conversion to resectability
6. If converted: Surgery followed by completion of 6 months total systemic therapy
7. If remains unresectable: Continue systemic therapy or consider ablative techniques for oligometastatic disease